Highlights

  • Artrya Limited (ASX:AYA) signed a five-year Huntsville hospital agreement.
  • September-quarter customer receipts totalled AUD 84,000.
  • Pro forma cash was AUD 67.2 million at September 30.
  • The planned Coronary Flow FDA filing requires additional evidence.

Artrya Limited develops software for assessing coronary artery disease from cardiac computed tomography angiography scans. On November 17, 2026, Artrya shares (ASX:AYA) traded at AUD 2.69, down 12.09% during the session. The company’s October operational update described further US hospital deployments of its Salix platform, a new commercial agreement and an adjusted regulatory work programme for Coronary Flow.

An AI Platform for Coronary Assessment

The Salix cloud platform is designed to support clinicians analysing coronary anatomy and plaque using cardiac CT images. Artrya (ASX:AYA) markets its FDA-cleared Coronary Anatomy and Coronary Plaque capabilities to US healthcare systems through subscription and per-scan commercial arrangements. The company is developing Coronary Flow as an additional module to examine the functional significance of coronary artery disease; that module had not received FDA clearance at the time of the September-quarter report.

Its commercial model depends on integration with hospital imaging and IT systems, clinician adoption and the Volume of scans processed. The company also runs the SAPPHIRE study with US healthcare organisations to generate clinical evidence and allow participating teams to gain experience with Salix. Study participation and a binding commercial customer agreement are different stages of adoption.

Huntsville Agreement and Hospital Deployment

In its October 26 quarterly announcement, Artrya (ASX:AYA) disclosed a five-year commercial agreement with Huntsville Hospital Health System, the first SAPPHIRE participant to become a commercial customer. The agreement carries a minimum value of US$0.5 million for the Coronary Anatomy subscription; Coronary Plaque use and any future cleared Coronary Flow assessments would attract additional per-scan charges.

Huntsville operates 15 hospitals and 19 heart centres across Alabama and Tennessee. Artrya said integration planning was underway. At Tanner Health, a pre-authorisation workflow introduced in mid-September was followed by increased use of the Coronary Plaque module. Northeast Georgia Health System was extending Salix beyond its initial site, while Cone Health continued implementation work after delays associated with its organisational transition.

Quarterly Cash and Regulatory Timetable

For the September 2026 quarter, Artrya (ASX:AYA) reported AUD 84,000 of customer receipts from subscription and per-scan activity. Operating costs excluding research-and-development rebates and interest were AUD 7.4 million, compared with AUD 6.5 million in the previous quarter. The company reported pro forma cash of AUD 67.2 million at September 30, alongside an AUD 4.8 million FY26 research-and-development rebate claim in progress.

A regulatory timetable adjustment was also disclosed. Following review of clinical study data, the company identified inconsistencies among expert-reader assessments within a sub-study. Artrya elected to conduct an additional reader study before submitting Coronary Flow to the US Food and Drug Administration. Its previous expectation of a submission and potential clearance by the end of 2026 was therefore extended; no revised filing date was specified.

Risks and Near-Term Monitoring

Artrya (ASX:AYA) remains exposed to hospital implementation schedules, product utilisation, reimbursement workflow, operating expenditure and the timing and outcome of regulatory review. Signed agreements do not automatically translate into immediate scan volumes. The planned additional evidence work may also affect the timing of Coronary Flow commercialisation.

Developments to monitor include Huntsville integration, the wider Northeast Georgia rollout, Cone Health deployment, plaque assessments at Tanner and future quarterly customer receipts. Updates on the additional reader study and any FDA filing will help distinguish product-development milestones from regulatory clearance.

SAPPHIRE study work continues alongside commercial negotiations. Huntsville’s conversion does not establish that other participants will sign comparable agreements. Future filings may distinguish clinical installations, fee-generating scans, contracted subscriptions and customer receipts.

Key Insights

Artrya (ASX:AYA) reported additional US commercial activity and early receipts during the September quarter, supported by cash raised for expansion. Its latest disclosure also replaced the earlier Coronary Flow timetable with further clinical-evidence work. Customer deployment and recurring utilisation remain central measures for subsequent reporting.